Tinnitus Research Digest: Neck Muscles, Chemotherapy Hearing Risk, and Gaze-Evoked Sounds

Study context: This cross-sectional study enrolled 161 adults who had been diagnosed with somatosensory tinnitus (ST) — the subtype in which neck or jaw dysfunction influences the tinnitus percept, estimated to affect around 25% of people with tinnitus. Participants underwent a comprehensive battery of physical assessments covering the cervical spine and jaw, including range of motion tests, joint repositioning accuracy, muscle strength and coordination measures, and screening for active myofascial trigger points. Tinnitus distress was measured with the Tinnitus Functional Index.

Findings: The results showed that ST patients consistently presented with physical abnormalities in the neck and jaw. Ninety-five out of 100 patients had at least one active myofascial trigger point, and one in four had active trigger points in every neck muscle tested. Half the sample showed trigger points in jaw muscles as well. Patients also showed reduced cervical joint repositioning accuracy, restricted range of motion, and diminished neck muscle strength and coordination. Scores on the Neck Bournemouth Questionnaire and TMD Pain Screener reflected these physical complaints.

Remaining questions: The study’s cross-sectional design means it cannot establish whether these physical dysfunctions cause somatosensory tinnitus or are a consequence of it. The sample, while relatively large for this subtype, was drawn from a clinical population, so findings may not apply to all ST patients. The authors note substantial variation in the pattern of dysfunctions across individuals, meaning a standardised one-size-fits-all treatment protocol is unlikely to be appropriate.

Study context: This single-centre, cross-sectional prospective study enrolled 110 adults scheduled to begin platinum-based chemotherapy (a treatment group known to carry risk of hearing damage). Before starting treatment, all participants underwent a battery of audiological tests including standard pure-tone audiometry, speech audiometry in quiet and noise, otoacoustic emissions, auditory brainstem responses, and vestibular assessments. The goal was to test whether this comprehensive pre-treatment protocol was feasible in a real oncology clinic setting.

Findings: The testing was largely achievable, though vestibular assessments were completed in only 65 of 110 patients (59%), limited by age, fatigue, and logistical factors. Before chemotherapy began, 44.5% of patients already had measurable hearing loss, 9.1% reported tinnitus, and 34.5% reported difficulty understanding speech in noise. Three patients were found to have an undiagnosed balance disorder (BPPV) prior to starting treatment. These pre-existing conditions are relevant because platinum-based drugs can cause additional cochlear damage, and patients with baseline deficits face a higher cumulative risk.

Remaining questions: This study describes baseline status only; it does not follow patients through or after chemotherapy to measure actual hearing decline. Whether early detection enabled by pre-treatment testing leads to meaningful interventions that reduce hearing loss remains an open question. Larger multi-centre studies tracking patients longitudinally are needed to answer that.

Study context: This is a case report — the lowest level of clinical evidence — describing a single individual with a condition called tensor tympani myoclonus, in which the small muscle of the middle ear contracts involuntarily. The patient reported hearing sounds specifically when she moved her eyes to extreme leftward positions. Researchers recorded these sounds using a microphone placed in her ear canal and compared them to known eye movement-related eardrum oscillations (EMREOs), a normal but typically inaudible phenomenon.

Findings: The sounds this patient heard could be measured objectively in her left ear. They were larger in amplitude and longer in duration than typical EMREOs seen in people without the condition. The authors interpret this as evidence that signals from eye movement control systems reach the tensor tympani muscle specifically, and that when the muscle is abnormal, these normally silent signals can become audible. The case extends the known causes of gaze-evoked tinnitus, which had previously been most commonly associated with acoustic neuromas.

Remaining questions: As a single case report, this observation cannot be generalised. It establishes a possible mechanism but does not indicate how common this pathway is, whether it applies to other forms of tinnitus that change with eye position, or what treatment options might follow from this understanding. Further case series and mechanistic research would be needed before any clinical implications could be drawn.